Breztri Aerosol, Metered
Product Images NDC 0310-6616

30 FDA label images from Astrazeneca Pharmaceuticals Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 30 technical images submitted to the FDA as part of the official labeling for Breztri (NDC 0310-6616). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astrazeneca Pharmaceuticals Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Budesonide Chemical Structure (Budesonidechemstructure)

Budesonide Chemical Structure (Budesonidechemstructure)
Chemical structure of budesonide, one of the active ingredients in BREZTRI aerosol, metered respiratory inhalation medication by AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Glycopyrrolate Chemical Structure (Glycopyrrolatechemstructure)

Glycopyrrolate Chemical Structure (Glycopyrrolatechemstructure)
Chemical structure diagram showing the molecular structure of glycopyrrolate, one of the active ingredients in BREZTRI inhalation aerosol.*
FDA Label Image

Formoterol Fumarate Chemical Structure (Formoterolfumaratechemstructure)

Formoterol Fumarate Chemical Structure (Formoterolfumaratechemstructure)
Chemical structure showing the molecular formula of formoterol fumarate dihydrate, one of the active ingredients in BREZTRI aerosol for inhalation by AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Figure_1 (Figure1)

Figure_1 (Figure1)
A line graph depicting the adjusted mean change from baseline in trough FEV1 (L) over 52 weeks post-dose. It compares three treatment groups: BREZTRI AEROSPHERE 320/18/9.6 mcg, GFF MDI 18/9.6 mcg, and BFF MDI 320/9.6 mcg. The graph shows FEV1 improvements peaking early then gradually declining over time for each group.*
FDA Label Image

Kalos_figure_2 (Kalos Figure 2)

Kalos_figure_2 (Kalos Figure 2)
A line graph comparing the LS mean change from baseline in mL over 24 weeks for BREZTRI AEROSPHERE 320/36/9.6 mcg and BFF MDI 320/9.6 mcg. The x-axis represents time in weeks from Day 0 to Week 24, and the y-axis shows the change in milliliters. Data points for both treatments include error bars, with BREZTRI AEROSPHERE generally showing higher values throughout the period, and the number of subjects at each time point listed below the x-axis.*
FDA Label Image

Logos_figure_2 (Logos Figure 2)

Logos_figure_2 (Logos Figure 2)
A line graph comparing the LS mean change from baseline in mL over 24 weeks for BREZTRI AEROSPHERE 320/36/9.6 mcg and BFF MDI 320/9.6 mcg. The graph shows time in weeks on the x-axis and LS mean change from baseline on the y-axis, with error bars representing 95% confidence intervals. The data points indicate measurements at baseline, week 4, 8, 12, 16, 20, and 24.*
FDA Label Image

2_ifu_parts_of_your_inhaler (Puffindicator)

2_ifu_parts_of_your_inhaler (Puffindicator)
An instructional diagram of the BREZTRI aerosol metered inhaler showing labeled parts: puff indicator attached at the top, pressurized canister inside holding the medicine, yellow actuator containing the canister, mouthpiece that sprays the medicine, and a protective mouthpiece cover.*
FDA Label Image

Reading_the_puff_indicator (Reading Puff Indicator 120)

Reading_the_puff_indicator (Reading Puff Indicator 120)
An instructional diagram explaining how to read a puff indicator on an inhaler. The diagram shows a circular dial with a pointer, marked with numbers from 0 to 120. It highlights the pointer indicating the number of puffs remaining, a yellow zone advising to order a new inhaler, and a red zone indicating to discard the inhaler when the pointer reaches zero.*
FDA Label Image

Prime_1 (Prime 1 120)

Prime_1 (Prime 1 120)
Instructional illustration showing how to prime the BREZTRI metered aerosol inhaler by removing the mouthpiece cover. Two hands squeeze both sides of the cover and pull it out as indicated by arrows.*
FDA Label Image

Prime_2 (Prime 2)

Prime_2 (Prime 2)
An instructional diagram titled "Prime 2" showing how to prime the BREZTRI AEROSPHERE inhaler. It illustrates shaking the inhaler and spraying 1 test-puff away from the user, repeating for a total of 4 test-puffs, with emphasis on shaking before each puff. The image includes stepwise hand movements and a side profile of a person performing the priming spray.*
FDA Label Image

Re_prime (Re Prime)

Re_prime (Re Prime)
Instructional text panel for BREZTRI inhaler re-priming procedures. It advises rinsing the yellow actuator, re-priming if dropped, or if unused for more than 7 days. Users are instructed to spray 2 test-puffs, shaking before each, totaling 2 shake and test-puffs.*
FDA Label Image

Step_1 (Step 1)

Step_1 (Step 1)
Instructional diagram for BREZTRI aerosol metered inhaler showing Step 1: remove the mouthpiece cover and check the mouthpiece for foreign objects before use, with an illustration of a person facing the inhaler mouthpiece.*
FDA Label Image

Step_2 (Step 2)

Step_2 (Step 2)
Illustrated step-by-step instructions for using a metered dose inhaler, showing shaking the inhaler, breathing out, placing the mouthpiece in the mouth with lips closed, inhaling deeply while spraying one puff, and holding breath up to 10 seconds. Each step is numbered from 2.1 to 2.5 with corresponding images of a person using the inhaler.*
FDA Label Image

Step_3_4_5 (Step 3 4 5)

Step_3_4_5 (Step 3 4 5)
An instructional diagram illustrating Steps 3 to 5 for using the BREZTRI aerosol inhaler. Step 3 instructs to repeat all parts in Step 2 for the second puff. Step 4 shows putting the mouthpiece cover back on the inhaler. Step 5 depicts rinsing the mouth with water and spitting it out without swallowing.*
FDA Label Image

Rinse_1_rinse_2 (Rinse 1 Rinse 2)

Rinse_1_rinse_2 (Rinse 1 Rinse 2)
An instructional diagram illustrating two rinse steps for a respiratory inhaler. The first panel shows removing the canister and setting it aside while keeping it dry. The second panel depicts removing the mouthpiece cover from the inhaler device.*
FDA Label Image

Rinse_3_and_4 (Rinse 3 4 120)

Rinse_3_and_4 (Rinse 3 4 120)
Illustrations demonstrating steps 3 and 4 for rinsing the BREZTRI aerosol inhaler actuator. Step 3 shows rinsing the mouthpiece and actuator top with warm water for 30 seconds each, totaling 60 seconds. Step 4 depicts shaking off excess water without drying the actuator with a towel or tissue.*
FDA Label Image

Rinse_3_rinse_5 (Rinse 3 Rinse 5)

Rinse_3_rinse_5 (Rinse 3 Rinse 5)
An instructional diagram showing steps 5 and 6 for rinsing a respiratory inhaler actuator. Step 5 depicts a person looking into the actuator and mouthpiece for medicine build-up, advising to repeat previous rinsing steps if needed. Step 6 shows the actuator parts separately, instructing to air-dry the actuator overnight and not to put the canister back into the actuator while it is still wet.*
FDA Label Image

Rinse_7_rinse_8 (Rinse 7 Rinse 8)

Rinse_7_rinse_8 (Rinse 7 Rinse 8)
An instructional diagram showing steps 7 and 8 to rinse and re-prime the BREZTRI aerosol metered inhaler. Step 7 depicts replacing the mouthpiece cover and pressing the canister into the actuator when dry. Step 8 instructs spraying 2 test-puffs with shaking between each to re-prime the inhaler, including a text box emphasizing '2 total shake and test-puffs.'*
FDA Label Image

2_ifu_parts_of_your_inhaler (Puffindicator 01)

2_ifu_parts_of_your_inhaler (Puffindicator 01)
An illustration diagram of the BREZTRI metered dose inhaler showing labeled parts: puff indicator on top of the pressurized canister, pressurized canister inside containing medicine, yellow actuator housing the canister, mouthpiece for spraying medicine, and a mouthpiece cover to protect it when not in use.*
FDA Label Image

Reading_the_ Puff_ Indicator (Image 02)

Reading_the_ Puff_ Indicator (Image 02)
An instructional illustration depicting three circular dose counters labeled Figure 2a, 2b, and 2c, showing remaining puffs on an inhaler device. The counters display 120 puffs, 110 puffs, and 100 puffs respectively, indicated by shaded segments and numeric values, representing different levels of remaining doses in the inhaler.*
FDA Label Image

Prime_1 (Image 03)

Prime_1 (Image 03)
Illustration of a circular dose counter dial for an aerosol medication inhaler, showing a numeric scale from 0 to 40 with an arrow indicator used to monitor remaining doses.*
FDA Label Image

Prime_2_2 (Prime 2 2)

Prime_2_2 (Prime 2 2)
Illustrated instructions for priming the BREZTRI Aerosphere inhaler. It shows a person shaking the inhaler and spraying one test-puff away from the face. The diagram indicates repeating this shaking and spraying for a total of four test-puffs, emphasizing not to skip priming, as extra puffs are provided for this purpose.*
FDA Label Image

Re_prime_2 (Re Prime 2)

Re_prime_2 (Re Prime 2)
Instruction panel for BREZTRI aerosol inhaler re-priming. Advises re-priming if the inhaler is dropped or unused for over 7 days. Directions specify spraying 2 test-puffs, shaking before each, totaling 2 shake and test-puffs to re-prime the device.*
FDA Label Image

Step_1 (Image 06)

Step_1 (Image 06)
An instructional illustration depicting the proper use of a metered-dose inhaler. The image shows a hand holding the inhaler with an arrow indicating to press down on the canister to release the aerosol while a person’s profile demonstrates inhaling the medication through the mouthpiece.*
FDA Label Image

Step_2_2 (Step 2 2)

Step_2_2 (Step 2 2)
Step 2 instructions for using the BREZTRI inhaler. The five-panel illustration shows: shaking the inhaler before each puff; breathing out fully; placing the mouthpiece in the mouth while closing lips around it; starting to breathe in deeply and slowly while spraying one puff; and holding breath for up to 10 seconds.*
FDA Label Image

Step_3_4_5_2 (Step 3 4 5 2)

Step_3_4_5_2 (Step 3 4 5 2)
An instructional illustration demonstrating Steps 3 to 5 for using a respiratory inhalation aerosol. Step 3 instructs to repeat all parts in Step 2 for the second puff. Step 4 shows putting the mouthpiece cover back on the inhaler. Step 5 advises rinsing the mouth with water and spitting it out, not swallowing. The image includes line drawings of hands handling the inhaler and a person rinsing their mouth at a sink.*
FDA Label Image

Carton_120 (Container)

Carton_120 (Container)
BREZTRI AEROSPHERE inhalation aerosol containing budesonide, glycopyrrolate, and formoterol fumarate at strengths of 160 mcg, 9 mcg, and 4.8 mcg per inhalation. The label shows the product is for oral inhalation only, includes directions to shake well before use, and provides 120 inhalations per container. Labeler is AstraZeneca Pharmaceuticals LP.*
FDA Label Image

Carton_28 (28 Carton)

Carton_28 (28 Carton)
Packaging label for BREZTRI Aerosphere inhalation aerosol by AstraZeneca Pharmaceuticals LP. The label shows the active ingredients budesonide, glycopyrrolate, and formoterol fumarate with strengths of 160 mcg, 9 mcg, and 4.8 mcg per inhalation. The inhaler contains 28 inhalations and is designated for oral inhalation only. Instructions include shaking well before use and discarding after the labeled number of inhalations or 3 weeks after opening the foil pouch.*
FDA Label Image

Breztri_asthma_160mcg (Breztri Asthma 160mcg)

Breztri_asthma_160mcg (Breztri Asthma 160mcg)
BREZTRI AEROSPHERE inhalation aerosol label showing budesonide, glycopyrrolate, and formoterol fumarate with strengths of 160 mcg, 18 mcg, and 4.8 mcg per inhalation. The label indicates 120 inhalations per canister and includes instructions for use, the AstraZeneca Pharmaceuticals LP logo, and an area for date foil pouch opened. It is marked Rx only and for oral inhalation use.*
FDA Label Image

Breztri_asthma_160mcg_28 (Breztri Asthma 160mcg 28)

Breztri_asthma_160mcg_28 (Breztri Asthma 160mcg 28)
BREZTRI Aerosphere inhalation aerosol containing budesonide, glycopyrrolate, and formoterol fumarate, labeled with strengths 160 mcg / 18 mcg / 4.8 mcg per inhalation. The packaging notes 28 inhalations per container and includes instructions to shake well before use. The labeler is AstraZeneca Pharmaceuticals LP.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.